United States: Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
OIG Focuses On Prevention In New Medicare Advantage Risk Adjustment Report
The Office of the Inspector General (OIG) continues to focus on Medicare Advantage (MA) risk adjustment payments, issuing a report this week detailing its audit of MA risk adjustment payments based on acute stroke diagnosis codes that do not have corroborating hospital records. OIG found that submissions for all 97 sampled enrollees were not supported in the enrollee’s medical records, estimating $462 million in potential net overpayments in 2021.
United States Healthcare
M
Mintz
Article
OHCA Releases Proposed Regulations Broadening Health Care Transaction Oversight In California
On May 15, 2026, the California Office of Health Care Affordability (OHCA) released proposed regulations implementing Assembly Bill (AB) 1415 which took effect on January 1, 2026 (see our prior posts here and here). The new legislation expands the state’s health care material change transaction notice (MCN) process and requires private equity groups, hedge funds, management services organizations (MSOs), and certain newly created entities to give OHCA direct notice of proposed material change transactions involving a health care entity.
United States Healthcare
M
Mintz
See more

Highlighted Content

Food and Drugs Law

Article
Supreme Court Clarifies Standard For Induced Infringement In Hikma v. Amarin
In a unanimous decision handed down today, the Supreme Court delivered a tactical victory for Hikma, and a measure of guidance for other generic manufacturers. In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, the Court held that drug manufacturer Amarin, the reference product sponsor, failed to state a claim for active inducement of patent infringement under 35 U.S.C. § 271(b).
United States IP
M
Mintz
See more

Life Sciences, Biotechnology & Nanotechnology

Article
Supreme Court Clarifies Standard For Induced Infringement In Hikma v. Amarin
In a unanimous decision handed down today, the Supreme Court delivered a tactical victory for Hikma, and a measure of guidance for other generic manufacturers. In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, the Court held that drug manufacturer Amarin, the reference product sponsor, failed to state a claim for active inducement of patent infringement under 35 U.S.C. § 271(b).
United States IP
M
Mintz
See more

Healthcare

Article
OIG Focuses On Prevention In New Medicare Advantage Risk Adjustment Report
The Office of the Inspector General (OIG) continues to focus on Medicare Advantage (MA) risk adjustment payments, issuing a report this week detailing its audit of MA risk adjustment payments based on acute stroke diagnosis codes that do not have corroborating hospital records. OIG found that submissions for all 97 sampled enrollees were not supported in the enrollee’s medical records, estimating $462 million in potential net overpayments in 2021.
United States Healthcare
M
Mintz
See more

Latest Videos

See more